SEATTLE, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced second quarter ended June 30, 2018 financial results and provided an update on recent company developments.

Steve Quay, President and CEO commented, We have made tremendous progress with our clinical programs. We opened enrollment in two phase 2 clinical studies: one study using our proprietary topical Endoxifen for breast density reduction, and another study using our proprietary oral Endoxifen for reducing breast cancer tumor cell activity in the window of opportunity between diagnosis of breast cancer and surgery. We also completed dosing and patient visits in our phase 1 study of topical Endoxifen in men. Our intraductal microcatheter immunoOncology pre-clinical program was launched and we contracted with an additional manufacturer for Endoxifen. We have had a very busy and productive first six months of 2018 as we continue the momentum in the advancement of our clinical programs. We are looking forward to announcing preliminary results from our phase 1 study of topical Endoxifen in men by September 30, 2018, added Dr. Quay.

Recent Corporate Developments

Atossas important recent developments include the following:

Q2 2018 Financial Results

For the three and six months ended June 30, 2018 and 2017, we had no revenue and no associated cost of revenue.

Total operating expenses were approximately $4.1 million and $6.0 million for the three and six months ended June 30, 2018, respectively, consisting of general and administrative (G&A) expenses of approximately $2.7 million and $4.1 million, respectively; and research and development (R&D) expenses of approximately $1.5 million and $1.9 million, respectively. For the previous year, total operating expenses were approximately $1.9 million and $3.6 million for the three and six months ended June 30, 2017, respectively, consisting of G&A expense of approximately $1.1 million and $2.2 million, respectively, and R&D expenses of $0.8 million and $1.4 million, respectively.

About Atossa Genetics

Atossa Genetics Inc., is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit http://www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossas drugs under development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Company Contact:

Atossa Genetics Inc.Kyle GuseCFO and General CounselOffice: 866 893-4927kyle.guse@atossagenetics.com

Investor Relations Contact:

Scott GordonCorProminence LLC377 Oak StreetConcourse 2Garden City, NY 11530Office: (516) 222-2560scottg@corprominence.com

Source: Atossa Genetics Inc.

Read more:
Atossa Genetics Announces Second Quarter 2018 Financial ...

Learn.Genetics visitors,

Were asking for your help. For over 20 years, the Learn.Genetics website has provided engaging, multimedia educational materials at no cost.

Learn.Genetics is one of the most-used science websites. Tens of millions of visitors come to our site each year to find the science and health information theyre looking for.

If Learn.Genetics is useful to you, please take a moment to donate even a few dollars from each of our visitors would add up to a significant amount!

Your support will help us keep Learn.Genetics free and available to everyone. It will also help us develop new content for you.

Please help us keep Learn.Genetics going!

Thank you, The Genetic Science Learning Center team creators of Learn.Genetics

See the original post here:
Basic Genetics

Seattle Genetics (NASDAQ:SGEN) saw salesof its only approved drug Adcetris jump substantially in the second quarter, thanks to the Food and Drug Administration approval for the frontline treatment of stage III and IV Hodgkin lymphoma, which was granted in the first quarter.

Metric

Q2 2018

Q2 2017

Year-Over-Year Change

Revenue

$170.2 million

$108.2 million

57%

Income from operations

($30.3 million)

($59.3 million)

N/A

Earnings per share

$0.47

($0.39)

N/A

Data source: Seattle Genetics.

Image source: Getty Images.

"This is the highest sequential quarter-to-quarter growth rate since the product was launched," said Darren Cline, Seattle Genetics' executive vice president of commercial, which shows how big the approval for frontline Hodgkin lymphoma was for the company.

Nevertheless, CEO Clay Siegall cautioned investors that the initial increase in usage might not continue at the same rate:

It takes time to build market share in a setting where the standard of care hasn't changed in 40 years. I mean, it just takes time, and we are off to a good start. Our commercial team was ready. They were ready. They jumped on this, and we got the rapid adopters in. But the rest of the time, we're going to be making stepwise moves up there.

Management is guiding for third-quarter Adcetris sales in the range of $130million to $135million, a 6.2% to 10.3% quarter-over-quarter increase.

The next growth opportunity for Adcetris will come from mature T-cell lymphoma in a clinical trial called Echelon-2, which is scheduled to read out early in the fourth quarter. The number of potential patients with mature T-cell lymphoma is about the same as frontline Hodgkin lymphoma, but the current treatment isn't particularly good. So it may be easier to get rapid adoption in mature T-cell lymphoma if the Echelon-2 results show Adcetris is substantially better than the current standard of care.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool recommends Seattle Genetics. The Motley Fool has a disclosure policy.

Go here to see the original:
Seattle Genetics' Latest Approval Is the Best Yet -- The ...

Diagnostic genetics services at Boston Medical Center provide expertise in the diagnosis and evaluation of genetic and developmental disorders for patients, including:

Medical geneticist Jodi Hoffman, MD and the genetics teammanagement services for adults who have inherited disorders, genetic conditions, or birth defects. Patients seen in this clinic often have connective tissue disorders (Marfan syndrome and Ehlers Danlos syndrome, etc) as well as neurofibromatosis types 1 and 2, tuberous sclerosis, Down syndrome, rare cancer syndromes, and others. Consultations are provided in the Yawkey Ambulatory Care Clinic, 6th floor. NOTE: This is the same location as pediatric genetics.

For an appointment call 617.414.4841 or fax 617.414.5741

For more information, please call: 617.638.4317

Center of Excellence in Sickle Cell DiseaseHemoglobin Diagnostic Reference LaboratoryFor more information, please call: 617.414.1024.Medical Director: David Chui, MD

Jodi Abbott, MDRobert Blatman, MDPhilip Connors, MS, CGCAviva Lee-Parritz, MDGlenn Markenson, MDLillian Sosa, MS, CGCChristina Yarrington, MD

For an appointment, call 617.414.2000Antenatal Testing Unit: Yawkey5th Floor

Our certified genetic counselors provide consultation and testing for cancer predisposition syndromes for people who have a strong personal or family history of certain types of cancer. Identifying a genetic cause for cancer in a family allows for increased surveillance and earlier detection for at risk family members. The team works with testing companies and insurance to obtain coverage for this testing. Consultations are provided in the Moakley Building, 3rd floor, at 830 Harrison Ave.

For an appointment call: 617.638.6428Referrals can be faxed to: 617.414.1558

Medical geneticist Jodi Hoffman, MD and the genetics teamprovide diagnostic and management services for children who are likely to have inherited disorders, genetic syndromes, or birth defects. Children with unusual physical characteristics, developmental days, autism, or atypical growth are often referred for a genetics evaluation to determine if a genetic condition could explain the constellation of features. A diagnosis may provide information important for future health management as well as connections with support groups, research opportunities, and other families who have children with related conditions. Consultations are provided in the Yawkey Ambulatory Care Clinic, 6th floor.

For an appointment call 617.414.4841 orfax 617.414.5741More information

Certified genetic counselors Philip Connorsand Lillian Sosa provide consultation and counseling in the antenatal unit at Boston Medical Center to women who are pregnant or considering a pregnancy. Reasons for visits include advanced maternal age, abnormal nuchal translucency or maternal serum screening, medication exposures, carrier status, and family history. Clinic is held in Boston Medical Centers Antental Center, Yawkey 5th Floor.

For an appointment call 617.414.2000 orfax 617.414.7657More information

For more information:

Raveen Basran, D.Phil. Director of Diagnostic Molecular Genetics ([emailprotected]: 617.414.5329)Tom Maher, MS, Laboratory Manager of Diagnostic Molecular Genetics ([emailprotected]: 617.414.5312)Dan Remick, MD Medical Director, Diagnostic Molecular GeneticsDownload Diagnostic Genetics Consent Form

Michael OBrien, MD Chief Anatomic PathologyCarl O'Hara, MD - Chief of Laboratory MedicineShi Yang, MD, Scientific DirectorDownload Tissue Based DMP Requisition Form

Nancy Miller, MD, Medical Director Microbiology ([emailprotected])Chris Andry, PhD, Administrative Director and Vice Chair for Pathology Operations and Management ([emailprotected])Neil ONeill, Senior Manager for Laboratory Medicine Operations([emailprotected]: 617.414.4737)

All molecular genetics testing at BMC should be processed via the BMC Laboratory. BMC uses Quest Diagnostics as a reference laboratory and performs some testing in house. Quest Diagnostics' highly trained geneticists and genetic counselors are available at 1.866.GENE.INFO, (1.866.436.3463)

Go here to read the rest:
Genetic Services | Boston Medical Center

The Department of Genetics and Human Genetics offers courses leading to the Master of Science and Doctor of Philosophy degrees . The program is associated with the Departments of Pediatrics and Biology so that students will not only learn to work creatively in their own field of special interest but will also be able to relate their findings to progress made in related disciplines.

The graduate programs in Genetics & Human Genetics are designed to confer the training standards that will develop students for degrees of Doctorate of Philosophy Masters, and M.D./Ph.D. degree(s). The graduate program is an interdepartmental entity built on a diverse platform.

The program is associated with the department of Pediatrics and department of Biology where students work creatively in their field of special interest but and be able to relate application and relevance to related clinical and science disciplines.

The degree programs are designed to provide a curricular foundation in human genetics for all enrolled students during their first year.Following this, guided by their academic adviser, students elect to pursue their area of interest in genetics . This is accomplished through a combination of elective courses offered in the Department and other departments of the University, as well as in the Washington Area Consortium of Universities. The Masters thesis and Doctoral dissertation research interests likewise can reflect a broad range of interests, provided a suitable research mentor is identified in the graduate faculty.

This training program design takes into account the fact that genetics is increasingly relevant within the framework of multiple biomedical research and scholarly pursuits. The program design also is intended to foster the important principle of collaborative research and scholarship among biomedical disiplines.

The graduate programs are research-oriented curriculum's in the study of genetic mechanisms related to the transition from normal to disease states and intended to prepare graduates to participate in laboratory research.

To be accepted into the Graduate Program in Genetics and Human Genetics, students must have a Bachelors degree from an accredited institution and a GPA of at least 3.0 or B equivalent. In addition, students must meet the University requirement(s) to take the Graduate Record Examination (and the TOEFL if applicable).

Students with a bachelor degree may enter the graduate program at the Masters level or directly into the Ph.D. program. Eligibility to be considered for direct admission as a Ph.D. student requires a cumulative GPA greater than 3.2 and prior research and/or training experience in during undergraduate school or during a previous Masters degree

Applicants are required to submit these items for consideration of acceptance and review of potential for success:

Students wishing to enter the master's program should have a baccalaureate degree and a cumulative GPA average of B or the equivalent. They also should have completed undergraduate courses in modern biology, chemistry through organic chemistry, general biochemistry, mathematics through calculus, and general genetics, or equivalent courses. These prerequisites apply regardless of specialization selected within the master's program.

Students with less than a B average or who have not completed all of the required undergraduate courses may be admitted conditionally if they have very high Graduate Record Examination scores and/or excellent recommendations.

Students may matriculate into the doctoral program, having completed a suitable Masters degree, provided they present evidence of previous research experience supported by excellent letters of recommendation, and grades above 3.2 average.

Students who do not meet these general criteria may be considered for the master's program as indicated above.

The degree programs are designed to provide a curricular foundation in human genetics during their first and second year. Following years students elect to pursue elective courses in their area of interest.

Classes for degree credits are gained through a combination of elective courses offered in the Department, other departments within the University, and from courses offered through the Washington Area Consortium of Universities.

To confer the degree of Masters in Science requires;

To confer the degree of Doctor of Philosophy requires;

The College of Medicine and the Graduate School jointly offer an integrated program that leads to both the M.D. and Ph.D. degrees without compromise in the customary substance of each of these degrees individually. Additionally, the curricular emphasis develops in the trainee the unique professional role perspective of the clinician/scientist/scholar. It also develops a particular appreciation for the urgent and unsolved health problems that are present in the population served by the Howard University Hospital and its affiliated clinical programs.

Application Process

Graduate departments that currently invite applications for Ph.D. study in this program are: Anatomy, Biochemistry and Molecular Biology, Biology, Chemistry, Communication Sciences and Disorders, Genetics and Human Genetics, Microbiology, Pharmacology, Physiology and Biophysics.

The steps in the application process are as follows:

The application for the M.D./Ph.D. program shou ld be returned to:

Kareem Washington, Ph.D.Director M.D./Ph.D. ProgramHoward University College of Medicine520 W Street, NWWashington, DC 20059email:kareem.washington @howard.edu

A student, with the advice of the director of graduate studies, may file for admission to candidacy.

Students in the Ph.D. program are required to spend at least three semesters in full-time residence, two of which must be consecutive.

See original here:
Genetics and Human Genetics | Graduate School